Gritstone bio, Inc is a biotechnology company based in Emeryville, CA that is dedicated to developing innovative immunotherapies for cancer and infectious diseases. Their approach involves leveraging artificial intelligence and unique delivery systems to stimulate the patient's immune system, enabling it to recognize and destroy tumors or virally infected cells. With a focus on T cell recognition and the generation of potent immune responses, Gritstone aims to extend the benefits of immunotherapy to a wider range of patients.
Through their proprietary platforms, Gritstone has developed a portfolio of immunotherapies, including personalized cancer vaccines targeting individual patient-specific mutations (GRANITE) and off-the-shelf neoantigen therapies utilizing shared driver mutations (SLATE). Additionally, the company is also working on next-generation vaccines for the treatment and prevention of infectious diseases, such as their collaboration with Gilead Sciences to develop a vaccine-based immunotherapy for HIV infection. With their cutting-edge research and development facilities in Pleasanton, Emeryville, and Cambridge, Gritstone is at the forefront of advancing the field of immunotherapy.
Generated from the website